CN112739376A - 用于治疗炎性肠疾病的组合物和方法 - Google Patents

用于治疗炎性肠疾病的组合物和方法 Download PDF

Info

Publication number
CN112739376A
CN112739376A CN201980049881.7A CN201980049881A CN112739376A CN 112739376 A CN112739376 A CN 112739376A CN 201980049881 A CN201980049881 A CN 201980049881A CN 112739376 A CN112739376 A CN 112739376A
Authority
CN
China
Prior art keywords
subject
agent
vaccine
antibody
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980049881.7A
Other languages
English (en)
Chinese (zh)
Inventor
W.肖菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Craftsman Biotechnology Co ltd
Original Assignee
Craftsman Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Craftsman Biotechnology Co ltd filed Critical Craftsman Biotechnology Co ltd
Publication of CN112739376A publication Critical patent/CN112739376A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1257—Gram-negative bacteria from Bacteridaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980049881.7A 2018-07-03 2019-07-03 用于治疗炎性肠疾病的组合物和方法 Pending CN112739376A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693798P 2018-07-03 2018-07-03
US62/693,798 2018-07-03
PCT/US2019/040601 WO2020010254A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
CN112739376A true CN112739376A (zh) 2021-04-30

Family

ID=69059935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980049881.7A Pending CN112739376A (zh) 2018-07-03 2019-07-03 用于治疗炎性肠疾病的组合物和方法

Country Status (12)

Country Link
US (1) US20210261651A1 (https=)
EP (1) EP3817771A4 (https=)
JP (1) JP2021529828A (https=)
KR (1) KR20210029217A (https=)
CN (1) CN112739376A (https=)
AU (1) AU2019297455A1 (https=)
BR (1) BR112021000025A2 (https=)
CA (1) CA3104402A1 (https=)
IL (1) IL279859A (https=)
MX (1) MX2021000069A (https=)
SG (1) SG11202012774TA (https=)
WO (1) WO2020010254A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116209750A (zh) * 2019-12-20 2023-06-02 西奈山伊坎医学院 用于治疗炎症性肠病的组合物和方法
CN116410324A (zh) * 2023-05-24 2023-07-11 西安交通大学医学院第一附属医院 一种肠道微生物脆弱拟杆菌毒素中和纳米抗体及其应用
WO2023137994A1 (zh) * 2022-01-20 2023-07-27 陕西海司诺维科技有限公司 结直肠癌相关脆弱拟杆菌毒素蛋白激活体的特异性纳米抗体Nb3.27及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202227394A (zh) * 2020-09-11 2022-07-16 美商工匠生物科技股份有限公司 細菌毒素之小分子抑制劑
KR102478205B1 (ko) * 2020-09-24 2022-12-15 경희대학교 산학협력단 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법
CN121285383A (zh) * 2023-02-21 2026-01-06 萨尔维图斯公司 重组噬菌体、益生菌疫苗和治疗剂、相关组合物以及使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791647A1 (en) * 2010-03-01 2011-09-09 Institut National De La Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
US20120027799A1 (en) * 2009-04-02 2012-02-02 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
US20120258135A1 (en) * 2010-07-26 2012-10-11 Harold David Gunn Immunogenic anti-inflammatory compositions
CN105434476A (zh) * 2015-10-29 2016-03-30 广州知易生物科技有限公司 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027799A1 (en) * 2009-04-02 2012-02-02 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
CA2791647A1 (en) * 2010-03-01 2011-09-09 Institut National De La Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
US20120258135A1 (en) * 2010-07-26 2012-10-11 Harold David Gunn Immunogenic anti-inflammatory compositions
CN105434476A (zh) * 2015-10-29 2016-03-30 广州知易生物科技有限公司 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOOTIEN 等: "Monoclonal antibodies specific for Bacteroides fragilis enterotoxins BFT1 and BFT2 and their use in immunoassays", PLOS ONE, vol. 12, no. 3, pages 2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116209750A (zh) * 2019-12-20 2023-06-02 西奈山伊坎医学院 用于治疗炎症性肠病的组合物和方法
WO2023137994A1 (zh) * 2022-01-20 2023-07-27 陕西海司诺维科技有限公司 结直肠癌相关脆弱拟杆菌毒素蛋白激活体的特异性纳米抗体Nb3.27及其应用
CN116410324A (zh) * 2023-05-24 2023-07-11 西安交通大学医学院第一附属医院 一种肠道微生物脆弱拟杆菌毒素中和纳米抗体及其应用

Also Published As

Publication number Publication date
AU2019297455A1 (en) 2021-02-04
KR20210029217A (ko) 2021-03-15
BR112021000025A2 (pt) 2021-04-06
SG11202012774TA (en) 2021-01-28
CA3104402A1 (en) 2020-01-09
US20210261651A1 (en) 2021-08-26
WO2020010254A1 (en) 2020-01-09
JP2021529828A (ja) 2021-11-04
MX2021000069A (es) 2021-05-31
IL279859A (en) 2021-03-01
EP3817771A4 (en) 2022-03-23
EP3817771A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
CN112739376A (zh) 用于治疗炎性肠疾病的组合物和方法
KR100426832B1 (ko) 위염, 위궤양 및 십이지장궤양의 예방 또는 치료에 사용되는 특이적 항체
JP6775424B2 (ja) リポ多糖を欠損する細胞構成要素をベースとしたアシネトバクター・バウマニワクチン
RU2623174C2 (ru) Вакцины и композиции против streptococcus pneumoniae
EP1708749B1 (en) Mucosal vaccine adjuvants containing bacterial flegellins as an active component
JP4769481B2 (ja) ポリ−γ−グルタミン酸含有免疫補強剤組成物
Habibi et al. Intranasal immunization with fusion protein MrpH· FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis
Fujimoto et al. Antigen-specific mucosal immunity regulates development of intestinal bacteria-mediated diseases
Su et al. Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice
JP2010502199A (ja) リコンビナントヘリコバクターピロリの経口ワクチン及びその調製方法
JP2024540918A (ja) リポ多糖（ｌｐｓ）欠損アシネトバクター・バウマニ多価ワクチン
JP2017513849A (ja) Ａ群レンサ球菌ワクチン
CA2353048C (en) Pharmaceutical composition useful in the prevention or treatment of peptic ulcers
CN113329766A (zh) 艰难梭菌多组分疫苗
JPH11510793A (ja) 胃腸病に対する鼻腔内ワクチン接種
US9119803B2 (en) Carious tooth vaccine and preparation method
Won et al. Multifaceted immune responses and protective efficacy elicited by a recombinant autolyzed Salmonella expressing FliC flagellar antigen of F18+ Escherichia coli
KR102040665B1 (ko) 약독화된 폐렴구균 균주를 포함하는 약제학적 조성물 및 이의 용도
Karam et al. A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from Proteus mirabilis against urinary tract infections
US20100330124A1 (en) Vaccine compositions and methods of use to protect against infectious disease
WO2018076049A1 (en) Immunogenic protein and method of use
Ko et al. Host-pathogen interactions in urinary tract infections
AU758555B2 (en) Peptides
RU2786222C1 (ru) Поликомпонентная вакцина для иммунопрофилактики и иммунотерапии заболеваний, вызываемых условно патогенными микроорганизмами
JP2005304471A (ja) 尿路感染症の予防及び治療のための組換えｄｎａ、プラスミド、形質転換微生物及び経口用ワクチン蛋白質

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210430